What is CRISPR Therapeutics's accounts receivable?

CRISPR Therapeutics (CRSP) reported accounts receivable of -$0 in Q1 2026.

What is the long-term trend for CRISPR Therapeutics's accounts receivable?

Over 5 years (2020 to 2025), CRISPR Therapeutics's accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $144K to $0.

What does accounts receivable mean?

Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.

CRISPR Therapeutics CRSP Accounts Receivable

Accounts Receivable at other companies

Arrowhead ResearchARWR

$15.69M+563%

Krystal Biotech, Inc.KRYS

$127.02M+23.0%

BridgeBio PharmaBBIO

$205.23M+78.0%

CG OncologyCGON

$1.28M+270%

Regeneron PharmaceuticalsREGN

$5.73B+3.1%

Gilead SciencesGILD

$5.54B+5.5%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's accounts receivable?: CRISPR Therapeutics (CRSP) reported accounts receivable of -$0 in Q1 2026.
What is the long-term trend for CRISPR Therapeutics's accounts receivable?: Over 5 years (2020 to 2025), CRISPR Therapeutics's accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $144K to $0.
What does accounts receivable mean?: Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.